Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 196

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1B
Chunk 196
---
4, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. 

    Date: March 24, 2025
      
    BOLT BIOTHERAPEUTICS, INC.

    By:
     
    /s/ William P. Quinn

    William P. QuinnPresident, Chief Executive Officer and Chief Financial Officer (Principal Executive and Financial Officer)

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints William P. Quinn as his or her true and lawful attorneys-in-fact and agents, each with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof. 

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. 

    Signature
      
    Title
     
    Date

    /s/ William P. QuinnWilliam P. Quinn
      
    President, Chief Executive Officer and Chief Financial Officer (Principal Executive and Financial Officer)
     
    March 24, 2025

    /s/ Sarah NemecSarah Nemec
      
    Senior Vice President, Finance (Principal Accounting Officer)
     
    March 24, 2025

    /s/ Brian O’CallaghanBrian O’Callaghan
    Chairman
        March 24, 2025

    /s/ Laura BernerLaura Berner
     
    Director
     
    March 24, 2025

    /s/ Kathleen LaPorteKathleen LaPorte
      
    Director
     
    March 24, 2025

    /s/ Jakob Dupont